Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 62Prostatic Neoplasms 44Lung Neoplasms 35Multiple Myeloma 34Neoplasms 27Colorectal Neoplasms 23Parkinson Disease 4, Autosomal Dominant Lewy Body 22Leukemia, Lymphocytic, Chronic, B-Cell 22Neoplasm Metastasis 20Ovarian Neoplasms 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 13Small Cell Lung Carcinoma 13Pancreatic Neoplasms 13Endometrial Neoplasms 13Myasthenia Gravis 12Leukemia, Myeloid, Acute 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Nasopharyngeal Carcinoma 11Triple Negative Breast Neoplasms 10Stomach Neoplasms 10Non-Muscle Invasive Bladder Neoplasms 10Lymphoma, Follicular 10Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Melanoma 8Colonic Neoplasms 8Lymphoma, Large B-Cell, Diffuse 7

Interventions

Panzyga 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Agammaglobulinemia × 30 days × Clear all
NCT04502030 2026-06-04

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Octapharma

Phase 3 Completed
247 enrolled
LymphoidOther hematologic neoplasm

Agammaglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡